Buy Danocrine (Danazol 50/100/200mg) Online - Pioneering Synthetic Androgen for Endometriosis and Hereditary Angioedema
Danocrine (Danazol 50/100/200mg) represents the pioneering synthetic androgen therapy that established medical treatment as effective option for endometriosis, fibrocystic breast disease, and hereditary angioedema — the medication providing hormonal disease management since Sterling Winthrop (now Sanofi) received original FDA approval in 1971. As the first effective non-surgical therapy for endometriosis, Danocrine transformed gynecological medicine by offering women a medication option instead of surgery for painful endometriosis. Manufactured by Serum Pharmaceuticals and Cipla India as bioequivalent generic under WHO-GMP quality standards, Danocrine offers three dose strengths (50 mg, 100 mg, 200 mg) enabling careful titration to achieve therapeutic effect while minimizing dose-dependent side effects.
Danazol works through multiple hormonal mechanisms distinct from all other pain medications. As a 17-alpha ethinyl testosterone derivative, danazol demonstrates weak androgenic activity with additional antiestrogenic and antiprogestogenic effects. Primary mechanism involves suppression of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, producing decreased ovarian estrogen production and creating a hypoestrogenic environment that promotes endometrial atrophy. Additional mechanisms include direct action on endometrial tissue causing atrophy, enzyme induction increasing complement C1 esterase inhibitor (mechanism for HAE prophylaxis), and weak androgenic effects. This produces endometrial atrophy relieving endometriosis pain, reduced breast tissue proliferation for fibrocystic disease, increased C1 esterase inhibitor preventing HAE attacks, and reduced menstrual flow. Clinical response: menstruation ceases within 4-8 weeks of adequate dosing, endometriosis pain improves over 2-6 months, fibrocystic breast pain decreases within 2-3 months, and HAE attack frequency reduces substantially.
Danocrine serves multiple hormonal disease indications. Primary uses include endometriosis with concomitant infertility as pioneering medical therapy; fibrocystic breast disease (mastopathy) reducing breast pain and cyst formation; hereditary angioedema (HAE) prophylaxis preventing life-threatening swelling episodes; primary menorrhagia heavy menstrual bleeding; premenstrual syndrome (PMS) severe symptoms; gynecomastia male breast enlargement; and primary precocious puberty in specific clinical situations.
Danocrine requires gradual dose titration starting at 200 mg BID-TID (endometriosis) or lower doses for other indications, adjusted based on response and tolerability. Multiple hepatic metabolism pathways, 4-5 hour half-life. Contraindicated in pregnancy (fetal virilization). Serum Pharmaceuticals and Cipla India manufacture under WHO-GMP standards.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- Endometriosis with Infertility: Endometriosis-related infertility responding to hormonal suppression;
- Endometriosis Pain: Chronic pelvic pain from endometrial implants responding to endometrial atrophy;
- Fibrocystic Breast Disease: Benign breast tissue changes with cysts and pain;
- Fibrocystic Mastopathy: Breast tissue mastopathy responding to hormonal modulation;
- Breast Pain: Cyclical breast pain from fibrocystic disease responding to therapy;
- Hereditary Angioedema: HAE prophylaxis preventing life-threatening swelling episodes;
- HAE Attack Prophylaxis: Prevention of hereditary angioedema exacerbations through C1 inhibitor induction;
- Primary Menorrhagia: Heavy menstrual bleeding without identified pathology;
- Heavy Periods: Excessive menstrual bleeding responding to menstrual suppression;
- Premenstrual Syndrome: Severe PMS symptoms responding to hormonal therapy;
- Severe PMS: Debilitating premenstrual symptoms including pain mood changes;
- Gynecomastia: Male breast enlargement responding to antiestrogenic therapy;
- Primary Precocious Puberty: Early puberty in specific clinical situations;
- Chronic Pelvic Pain: Endometriosis-related chronic pelvic pain requiring hormonal therapy;
- Menstrual Pain: Severe dysmenorrhea from endometriosis or menorrhagia;
- Endometrial Atrophy Therapy: Medical induction of endometrial atrophy as endometriosis treatment;
- Synthetic Androgen Class: Drug class targeting hormonal disease through weak androgen action;
- Non Surgical Endometriosis Therapy: Medical alternative to surgery for endometriosis management;
- Generic Danocrine Therapy: Bioequivalent generic alternative to brand-name Danocrine at substantially lower cost.
- Better Endometrial Atrophy: Endometrial tissue atrophies through hormonal suppression relieving pain;
- Less Menstrual Bleeding: Menstruation ceases within 4-8 weeks of adequate dosing;
- Better Endometriosis Fertility Support: Endometrial disease treatment may improve fertility outcomes;
- Less Fibrocystic Breast Pain: Cyclical breast pain from fibrocystic disease decreases within 2-3 months;
- Less Breast Cyst Formation: Fibrocystic breast tissue changes reduce with hormonal therapy;
- Less Hereditary Angioedema Attacks: HAE episode frequency reduces substantially preventing life-threatening swelling;
- Better C1 Esterase Inhibitor Levels: Enzyme induction increases protective C1 inhibitor for HAE prevention;
- Less Menorrhagia: Heavy menstrual bleeding decreases substantially with therapy;
- Better Menstrual Cycle Control: Hormonal suppression enables predictable menstrual management;
- Less PMS Symptoms: Severe premenstrual syndrome symptoms improve with hormonal therapy;
- Less Chronic Pelvic Pain: Endometriosis-related pelvic pain decreases enabling normal activities;
- Less Male Breast Enlargement: Gynecomastia responds to antiestrogenic therapy;
- Better Non Surgical Endometriosis Option: Medical alternative avoiding surgery for endometriosis;
- Better Life Threatening HAE Prevention: Prevents laryngeal edema HAE attacks that can be fatal;
- Better Endometriosis Long Term Management: Sustained endometriosis control enabling normal lifestyle;
- Better Three Dose Flexibility: 50, 100, and 200 mg strengths enable careful titration;
- Better Historical Track Record: Over 50 years of clinical experience since FDA approval 1971;
- Better Generic Cost: 85-95% lower cost than brand Danocrine makes proven hormonal therapy accessible;
- Better Quality of Life: Daily wellbeing improves dramatically as endometriosis pain fibrocystic disease or HAE attacks resolve.
Generic Danocrine (Danazol 50 mg) Medication guide:
Danocrine (Danazol 50/100/200mg) is the pioneering synthetic androgen therapy that established medical treatment as an effective option for endometriosis, fibrocystic breast disease, and hereditary angioedema. Developed by Sterling Winthrop Pharmaceuticals and FDA-approved in 1971, danazol became the first medication providing effective non-surgical therapy for endometriosis — transforming gynecological medicine by offering women a hormonal option instead of surgery for painful endometrial disease. As a weak synthetic androgen derived from 17-alpha ethinyl testosterone, danazol works through multiple hormonal mechanisms including pituitary gonadotropin suppression, direct endometrial atrophy effects, and enzyme induction that increases protective C1 esterase inhibitor for hereditary angioedema prophylaxis. This comprehensive medication guide covers every aspect of Danocrine therapy from disease pathophysiology through mechanism, pharmacology, safety considerations, drug interactions, patient selection, dosing strategies, and long-term management.
💊 Introduction to Danocrine
Danocrine is a prescription oral medication containing danazol as its active ingredient. Danazol was developed by Sterling Winthrop Pharmaceuticals and received FDA approval in the United States in 1971. Sterling Winthrop later merged into Sanofi, which continues to hold the Danocrine brand internationally. When introduced, Danocrine represented a therapeutic breakthrough as the first effective medical (non-surgical) therapy for endometriosis — a chronic painful gynecological condition that previously required surgical intervention for adequate control.
The medication is manufactured worldwide by numerous generic pharmaceutical companies following patent expiration. The version sold under the Danocrine brand name on rxshop.md is manufactured by Serum Pharmaceuticals and Cipla India — two established Indian pharmaceutical companies with WHO-GMP certified facilities. This dual-manufacturer arrangement provides broader supply chain reliability and quality assurance. Available in three dose strengths (50 mg, 100 mg, 200 mg oral capsules), Danocrine enables careful dose titration to achieve therapeutic effect while minimizing dose-dependent side effects — an important feature given danazol pronounced side effect profile.
Danocrine holds a distinctive position in modern medicine. Once the gold standard therapy for endometriosis in the 1970s-1990s, danazol has been substantially replaced as first-line therapy by GnRH agonists (leuprolide, goserelin) that produce similar hypoestrogenic effects with better side effect profiles. However, danazol remains clinically important for several reasons: it provides an oral therapy option (GnRH agonists require injection), it offers substantially lower cost than newer therapies, it has over 50 years of clinical experience providing well-characterized safety, and it remains the preferred long-term prophylactic therapy for hereditary angioedema where its enzyme-inducing effect on C1 esterase inhibitor is particularly valuable and often superior to alternatives.
🔬 Understanding Endometriosis Pathophysiology
Understanding endometriosis is essential for appreciating how Danocrine treats this common and often debilitating condition.
What Is Endometriosis
Endometriosis is a chronic gynecological disorder characterized by the presence of endometrial-like tissue outside the uterus (ectopic endometrial tissue). This ectopic tissue responds to hormonal cycles similarly to normal endometrial tissue — proliferating during the menstrual cycle and bleeding at menstruation. Because this blood has no way to exit the body, it causes:
Endometriosis clinical consequences:
- Chronic pelvic pain: Progressive worsening pelvic pain particularly during menstruation
- Dysmenorrhea: Severe menstrual cramps often disabling
- Dyspareunia: Painful intercourse
- Dyschezia: Painful bowel movements particularly during menstruation
- Dysuria: Painful urination
- Infertility: 30-50 percent of endometriosis patients experience infertility
- Ovarian cysts: Endometrioma (chocolate cysts) formation
- Bowel and bladder involvement in advanced disease
- Adhesions and fibrosis: Scar tissue causing organ dysfunction
Common Endometriosis Locations
Endometrial implants commonly develop at these sites:
- Ovaries: Most common site with endometrioma formation
- Fallopian tubes: Contributing to infertility
- Peritoneal surfaces: Anywhere in the pelvis
- Pouch of Douglas: Space behind the uterus
- Uterosacral ligaments: Support structures of uterus
- Bladder and bowel surfaces: Causing organ-specific symptoms
- Diaphragm: Rare but documented
- Distant sites: Lungs, brain (very rare)
Treatment Approach
Endometriosis treatment aims to reduce estrogen stimulation of ectopic endometrial tissue, causing atrophy and symptom relief. Modern approach includes:
- NSAIDs: First-line for mild symptoms
- Combined oral contraceptives: Suppressing ovulation and reducing menstruation
- Progestins: Inducing endometrial atrophy
- GnRH agonists (leuprolide): Producing pseudomenopause suppressing ovaries
- Danazol: Weak androgen creating hypoestrogenic hyperandrogenic environment
- Surgery: For advanced disease or infertility
🔬 Understanding Fibrocystic Breast Disease
Fibrocystic breast disease (fibrocystic mastopathy) is the most common benign breast condition, affecting up to 50 percent of women. Characterized by lumpy tender breast tissue with cyclical changes related to menstrual cycle hormones, fibrocystic disease represents an exaggerated normal breast tissue response to cyclical hormonal changes.
Fibrocystic disease features:
- Cyclical breast pain (mastalgia) - worse before menstruation
- Breast lumps and cysts - firm, tender, mobile
- Breast tissue density increased particularly upper outer quadrants
- Nipple discharge in some cases
- Cyclical variation with menstrual cycle
- Bilateral usually but may be asymmetric
- Not associated with increased cancer risk in typical cases
Danocrine reduces fibrocystic breast pain through hormonal modulation — reducing estrogen stimulation of breast tissue that drives cyclical pain and cyst formation.
🔬 Understanding Hereditary Angioedema (HAE)
Hereditary angioedema (HAE) is a rare genetic disorder causing episodes of severe swelling. Danocrine is FDA-approved for HAE prophylaxis, providing life-saving prevention of potentially fatal attacks.
HAE Pathophysiology
HAE results from deficient or dysfunctional C1 esterase inhibitor — a protein that regulates the complement system and kallikrein-kinin system. Deficiency leads to uncontrolled bradykinin production, causing vascular permeability increases and characteristic swelling episodes. Attacks affect:
- Extremities: Painful non-pitting swelling of hands, feet, arms, legs
- Face: Facial swelling
- Abdomen: Severe abdominal pain from intestinal wall edema
- Larynx: Potentially fatal laryngeal edema requiring emergency intervention
- Genital area: Genital swelling
Danocrine treats HAE through enzyme induction — increasing hepatic synthesis of C1 esterase inhibitor to compensate for the underlying deficiency. This mechanism is distinct from danazol other actions and provides the basis for HAE prophylaxis.
🧬 Chemistry and Pharmacology of Danazol
Danazol has the chemical formula C22H27NO2 with molecular weight approximately 337.5 g/mol. Structurally, danazol is a 17-alpha ethinyl testosterone derivative — chemically related to natural androgens but modified to provide distinctive pharmacological properties including reduced androgenic potency, oral bioavailability (via 17-alpha ethinyl group), and antiestrogenic activity.
Mechanism of Action
Danazol produces its therapeutic effects through multiple hormonal mechanisms:
Danazol multi-mechanism action:
- Pituitary gonadotropin suppression: Reduces LH and FSH release from anterior pituitary
- Decreased ovarian estrogen: Reduced FSH/LH decreases ovarian estradiol production
- Hypoestrogenic environment: Creates low-estrogen state promoting endometrial atrophy
- Direct endometrial effects: Acts directly on endometrial tissue causing atrophy
- Weak androgen receptor binding: Provides weak direct androgenic activity
- Antiestrogenic activity: Competes with estradiol at estrogen receptors
- Antiprogestogenic activity: Additional hormonal modulation
- Sex hormone-binding globulin (SHBG) reduction: Increases free testosterone availability
- C1 esterase inhibitor induction: Hepatic enzyme induction increases protective enzyme for HAE
- Immunomodulation: Additional immune system effects
Pharmacokinetic Profile
| Parameter | Value | Clinical Significance |
|---|---|---|
| Onset of clinical effect | Days to weeks | Not for acute symptom relief |
| Menstruation cessation | 4 to 8 weeks at adequate dose | Indicates effective ovarian suppression |
| Endometriosis pain improvement | 2 to 6 months | Sustained therapy needed for full effect |
| Half-life (parent) | 4 to 5 hours | Requires BID-TID dosing for consistent levels |
| Metabolism | Extensive hepatic (multiple pathways) | Hepatic impairment affects clearance |
| Elimination | Biliary and renal | Both hepatic and renal function relevant |
| Food effect | Enhances absorption | Take with food for consistent levels |
| Protein binding | Highly protein bound | Displacement interactions possible |
🎯 Approved Indications
FDA Approved Indications
- Endometriosis — with associated pain, infertility, or advanced disease
- Fibrocystic breast disease — for pain management in severe cases
- Hereditary angioedema (HAE) — prophylaxis of attacks
Additional Uses (Approved in Various Countries)
- Primary menorrhagia — heavy menstrual bleeding
- Premenstrual syndrome — severe PMS symptoms
- Primary precocious puberty — early puberty management
- Gynecomastia — male breast enlargement
Off-Label Uses
- Immune thrombocytopenic purpura (ITP): Alternative treatment for chronic ITP
- Autoimmune hemolytic anemia: Second-line therapy
- Systemic lupus erythematosus: Adjunctive therapy in specific situations
- Aplastic anemia: Occasional use
- Myelodysplastic syndromes: Investigational use
Ideal Patient Selection
Danocrine therapy is most appropriate for:
- Endometriosis patients where GnRH agonists not preferred or affordable
- HAE patients requiring effective long-term prophylaxis
- Fibrocystic breast disease patients with severe pain unresponsive to first-line therapy
- Menorrhagia patients requiring hormonal management
- Patients who can tolerate androgenic side effects
- Patients using reliable non-hormonal contraception (Danocrine does not prevent pregnancy but should not be taken during pregnancy)
- Adult patients (or older adolescents for HAE) with confirmed indication
- Patients without contraindications including pregnancy, severe liver disease, or hormone-sensitive tumors
🚫 Contraindications
Absolute contraindications include:
- Pregnancy - X category due to fetal virilization risk
- Breastfeeding - excreted in breast milk with androgenic effects on infant
- Undiagnosed abnormal genital bleeding - requires diagnosis before hormonal therapy
- Severe hepatic dysfunction - danazol is hepatotoxic
- Markedly impaired renal function
- Severe cardiac dysfunction
- Hormone-sensitive tumors including some breast cancers
- Porphyria - danazol may precipitate acute attacks
- History of thromboembolic disease
Relative contraindications requiring caution:
- Cardiovascular disease including hypertension, heart failure
- Diabetes mellitus - may affect glucose control
- Epilepsy - may lower seizure threshold
- Migraine - may worsen migraines
- Polycythemia - danazol may worsen
- Lipid disorders - decreases HDL increases LDL
- History of prostate cancer in men - androgenic stimulation
⚠️ Serious Safety Warnings
Voice Changes May Be Permanent
Voice deepening may be irreversible:
Danazol androgenic effects can cause voice deepening (dysphonia) that may be permanent even after medication discontinuation. This is particularly important for:
- Professional voice users (singers, actors, speakers, teachers)
- Young women where identity concerns may be significant
- Long-term therapy patients where cumulative risk increases
At first sign of voice changes, discontinuation should be considered. Even brief voice change may not fully reverse. Discuss thoroughly before initiating therapy in vulnerable patients.
Fetal Virilization Risk (Pregnancy Category X)
Absolute contraindication in pregnancy:
Danazol causes virilization of female fetuses when used during pregnancy. Effects include ambiguous genitalia, clitoral enlargement, and labial fusion. Because ovulation may occur despite therapy in some patients, reliable non-hormonal contraception is essential during Danocrine use. Pregnancy testing before initiation is recommended.
Hepatotoxicity
Liver toxicity risks:
- Elevated liver enzymes in 15 percent of patients
- Cholestatic jaundice - rare but reported
- Peliosis hepatis - rare blood-filled liver lesions
- Hepatic adenoma - benign liver tumors with long-term use
- Hepatocellular carcinoma - very rare but reported
Monitor liver function tests at baseline, 6-month intervals, and if symptoms develop. Discontinue for significant enzyme elevations.
Increased Intracranial Pressure
Rare cases of benign intracranial hypertension (pseudotumor cerebri) reported. Symptoms include severe headache, vision changes, nausea, and papilledema. Discontinue immediately if suspected.
💉 Dosage and Administration
Endometriosis Dosing
Endometriosis standard dosing:
- Starting dose: 400 mg BID (800 mg/day) for moderate-severe endometriosis
- Mild-moderate cases: 200-400 mg daily divided BID
- Duration: Typically 3-6 months (up to 9 months maximum)
- Initiation timing: During menstruation to ensure not pregnant
- Adjustment: Reduce dose after menstruation ceases and symptoms improve
- Maintenance: Lowest dose maintaining symptom control (often 200 mg BID)
Fibrocystic Breast Disease Dosing
- Starting dose: 100-400 mg daily in divided doses
- Titration: Adjust based on response
- Duration: Typically 3-6 months
- Response assessment: At 3 months evaluate need for continuation
Hereditary Angioedema Dosing
HAE prophylaxis dosing:
- Starting dose: 200 mg BID or TID
- Attack-free period achieved: Reduce dose to lowest effective
- Maintenance: Often 100-200 mg daily is adequate
- Long-term therapy: HAE requires chronic prophylaxis
- Adjustment: Based on attack frequency and severity
Administration Guidelines
- Take with food to enhance absorption and improve tolerability
- Divide doses evenly throughout day given short half-life
- Take at consistent times each day
- Do not exceed 800 mg daily for endometriosis
- Do not exceed maximum recommended duration for indication
- Use reliable non-hormonal contraception during therapy
- Notify physician immediately of any pregnancy suspicion
- Report any voice changes immediately
📊 Clinical Effectiveness Data
| Indication | Response Rate |
|---|---|
| Endometriosis symptom relief (6 months therapy) | 70-90 percent significant improvement |
| Endometriosis fertility improvement | 30-50 percent pregnancy rate after therapy |
| Fibrocystic breast pain relief | 70-80 percent significant improvement |
| HAE attack frequency reduction | Substantial reduction in most patients |
| HAE laryngeal attack prevention | Dramatic reduction in life-threatening attacks |
| Menorrhagia bleeding reduction | 50-70 percent bleeding reduction |
| Amenorrhea induction (endometriosis dose) | 75-90 percent within 4-8 weeks |
⚠️ Side Effect Profile
Androgenic Side Effects (Most Common)
Given danazol weak androgen activity, most common side effects are androgenic:
- Weight gain: Very common - fluid retention and/or muscle mass
- Acne: Very common - androgenic sebum stimulation
- Oily skin and hair: Common
- Hirsutism (excess facial/body hair): Common - may be slow to reverse
- Voice deepening (dysphonia): Potentially irreversible
- Menstrual cessation: Expected therapeutic effect
- Hot flashes: Common from hypoestrogenic state
- Vaginal dryness: Common from hypoestrogenic state
- Reduced breast size: Common with prolonged use
- Muscle cramps: Common
- Mood changes: Anxiety, depression, irritability
Metabolic Side Effects
- Decreased HDL cholesterol: 50 percent reduction possible
- Increased LDL cholesterol: Adverse lipid effect
- Insulin resistance: May affect diabetes management
- Weight gain: Metabolic and fluid factors
- Edema: Sodium and water retention
Other Side Effects
- Headache: Common
- Dizziness: Common
- Sleep disturbance: Common
- Nervousness: Common
- Fatigue: Common
- Nausea: Common early in therapy
- Elevated liver enzymes: 15 percent of patients
- Rash: Occasional
Serious Side Effects Requiring Immediate Attention
Seek immediate medical attention for:
- Voice changes: Any deepening or hoarseness - potentially irreversible
- Signs of pregnancy: Missed period despite therapy, positive test
- Severe headache with vision changes: Possible pseudotumor cerebri
- Signs of liver injury: Jaundice, dark urine, right upper abdominal pain, unusual fatigue
- Signs of thromboembolism: Leg swelling, chest pain, shortness of breath
- Signs of stroke: Sudden weakness, speech difficulties, vision changes
- Severe allergic reactions: Rash, swelling, difficulty breathing
- Persistent nausea and vomiting
- Signs of increased intracranial pressure: Severe headache, vision blurring
- Any new mass or unusual bleeding
🔄 Drug Interactions
Major Interactions
| Drug | Interaction |
|---|---|
| Warfarin | Enhanced anticoagulant effect - monitor INR closely |
| Insulin and oral hypoglycemics | May require dose adjustment - insulin resistance |
| Cyclosporine, tacrolimus | Increased immunosuppressant levels - monitor |
| Carbamazepine | Increased carbamazepine levels - monitor toxicity |
| Statins | Increased risk of myopathy and rhabdomyolysis |
| Tamoxifen | Possible altered efficacy - use with caution |
| Hormonal contraceptives | Do not rely on for contraception - use non-hormonal |
| Alcohol | Increased hepatotoxicity risk |
🛡️ Special Populations
- Women of Reproductive Age
- Absolute pregnancy contraindication requires reliable non-hormonal contraception throughout therapy. Pregnancy testing before initiation. Danazol does not reliably prevent ovulation particularly at lower doses. Discuss family planning and future pregnancy plans thoroughly.
- Elderly Patients
- Increased sensitivity to androgenic effects. May have reduced hepatic metabolism. Cardiovascular risk from lipid effects more concerning. Consider alternatives when possible. Start at lower doses if needed.
- Adolescents
- HAE indication may require pediatric use. Growth effects possible - monitor. Androgenic effects on developing patients concerning. Specialist consultation recommended.
- Male Patients
- Used for HAE prophylaxis and gynecomastia. Generally better tolerated than in women. Monitor prostate health and lipid effects. Prostate cancer contraindication.
- Hepatic Impairment
- Contraindicated in severe hepatic impairment. Use with caution in mild-moderate impairment. Monitor liver function tests frequently. Discontinue for significant enzyme elevations.
- Renal Impairment
- Contraindicated in severe renal impairment. Fluid retention concerning. Use with caution in moderate impairment.
- Diabetic Patients
- Insulin resistance may worsen glucose control. Monitor blood glucose closely. May require diabetes medication adjustment.
🔬 Comparison with Alternative Therapies
| Property | Danocrine | GnRH agonists (leuprolide) | Progestins |
|---|---|---|---|
| Route | Oral | Injection | Oral, IM, IUD |
| Endometriosis efficacy | Effective | Effective | Effective |
| Side effect profile | Androgenic effects | Menopausal symptoms | Progestogenic effects |
| Voice change risk | Yes - potentially permanent | No | No |
| Bone density effect | Minimal | Significant loss | Variable |
| HAE prophylaxis | First-line | Not used | Not used |
| Cost | Lower (generic) | Higher | Variable |
| Duration limits | 6-9 months typical | 6 months (add-back allows longer) | Long-term use possible |
📆 Long-Term Use Considerations
Long-term monitoring for chronic HAE therapy:
- Liver function tests: Every 6 months given hepatotoxicity risk
- Lipid profile: Annually given adverse lipid effects
- Complete blood count: Periodically
- Blood pressure monitoring: Regular
- Voice monitoring: Any changes require immediate reassessment
- Pregnancy testing: If pregnancy possible
- Bone density (with GnRH combination): If applicable
- Hepatic imaging: Consider periodic ultrasound for adenoma detection with prolonged use
- Reassess ongoing need: Try lowest effective dose
- For endometriosis: Duration limited to 6-9 months typically
Post-Therapy Considerations
After stopping Danocrine:
- Menstruation typically resumes within 60-90 days
- Fertility returns for endometriosis patients seeking pregnancy
- Androgenic side effects gradually resolve except voice changes (may be permanent)
- Weight and lipid changes reverse in most patients
- Endometriosis may recur requiring retreatment or alternative therapy
- For HAE: Attacks resume - need continuous prophylaxis or replacement therapy
📦 Storage and Handling
- Store at room temperature between 15°C and 30°C (59°F and 86°F)
- Keep in original blister packaging to protect from light and moisture
- Avoid storage in bathrooms where humidity fluctuates significantly
- Keep out of reach of children and pets
- Do not use capsules past the expiration date printed on packaging
- Return unused or expired medication to pharmacy for proper disposal
- Never share danazol with others as doses and indications vary significantly
- Maintain adequate supply particularly for HAE prophylaxis to prevent interruption
👨⚕️ When to Contact Your Doctor
- Any voice changes or deepening - potentially irreversible
- Suspected pregnancy or missed contraception
- Signs of liver problems: jaundice, dark urine, unusual fatigue, right upper abdominal pain
- Severe headache with vision changes suggesting pseudotumor cerebri
- Signs of thromboembolism: leg swelling, chest pain, shortness of breath
- Signs of stroke: sudden weakness, speech difficulties, vision loss
- Severe allergic reactions or rash
- Signs of increased intracranial pressure
- Excessive weight gain or edema
- Severe mood changes or depression
- Persistent nausea and vomiting
- Blood pressure elevations
- Blood glucose control changes if diabetic
- Any new mass or unusual bleeding
- Starting new medications especially warfarin, statins, immunosuppressants
- Persistent symptoms not improving with therapy
🌟 Key Takeaways
Essential points about Danocrine (danazol) therapy:
- Danocrine is pioneering synthetic androgen FDA-approved in 1971 by Sterling Winthrop
- First effective medical (non-surgical) therapy for endometriosis
- Works through multi-mechanism: pituitary suppression, endometrial atrophy, C1 esterase inhibitor induction
- Three dose strengths (50, 100, 200 mg) enable careful titration
- Approved for endometriosis, fibrocystic breast disease, hereditary angioedema prophylaxis
- Take with food; divide doses BID-TID given 4-5 hour half-life
- Endometriosis pain improvement over 2-6 months of therapy
- HAE attack frequency substantially reduced enabling life-threatening attack prevention
- Voice deepening may be irreversible - discontinue at first sign
- Absolute contraindication in pregnancy due to fetal virilization
- Reliable non-hormonal contraception required during therapy
- Monitor liver function every 6 months given hepatotoxicity risk
- Adverse lipid effects (decreased HDL, increased LDL) require monitoring
- Largely replaced by GnRH agonists for endometriosis but remains preferred for HAE prophylaxis
- Duration typically limited to 6-9 months for endometriosis
Important Medical Disclaimer: This medication guide provides general information about Danocrine (danazol) and does not constitute individualized medical advice. Every patient situation is unique and requires evaluation by a qualified healthcare provider before starting continuing adjusting or discontinuing any medication. Do not use Danocrine without prescription from a qualified healthcare professional who has evaluated your specific medical situation and confirmed appropriate patient selection. This medication is absolutely contraindicated in pregnancy due to fetal virilization risk - reliable non-hormonal contraception is essential. Voice changes may be irreversible - discontinue at first sign of voice deepening. Report immediately any signs of liver injury, pregnancy, thromboembolism, or severe adverse effects. Monitor for lipid changes and glucose control changes. If you experience concerning symptoms contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance.
Danocrine — Frequently Asked Questions
-
What is Danocrine (Danazol)?
Danocrine is a synthetic steroid used to treat endometriosis, fibrocystic breast disease, and hereditary angioedema. -
How does Danocrine work?
It works by altering hormone levels, which can help reduce symptoms of the conditions it treats. -
What conditions does Danocrine treat?
It's primarily used for endometriosis, fibrocystic breast disease, and hereditary angioedema. -
How quickly does Danocrine start working?
The onset of action varies, but some patients may see improvement in symptoms within several weeks. -
How long do the effects of Danocrine last?
The effects can continue as long as the medication is taken. -
Can Danocrine be used for general hormone imbalances?
It is not typically used for general hormone imbalances without a specific diagnosis. -
What are the side effects of Danocrine?
Common side effects include weight gain, acne, oily skin or hair, voice changes, and mood swings.
See all Danocrine questions (32)
More Pain Medicine Medications
